In a bid to bolster its pipeline, Amgen has agreed to acquire Teneobio to discover, develop and commercialise new molecules for the treatment of wide range of diseases. The deal, which is worth up to US$2.5 B, gives Amgen access to Teneobio’s technology platform (UniAbs®) and several preclinical oncology pipeline assets including TNB-585. Interestingly, in its effort to mitigate the over-reliance on its current portfolio, Amgen has been actively engaged in acquisition activity during 2021.